“…Accordingly, there may be some value in implementing IMT in patients with conditions such as sarcoidosis [53], obesity [54], type 1 diabetes mellitus [55], idiopathic pulmonary hypertension [56], amyotrophic lateral sclerosis [57], hypothyroidism [58], arthritis [59,60] or cancer [61,62]. Furthermore, there are a small number of randomised, controlled trials in which IMT has elicited a positive effect upon dyspnoea in cystic fibrosis [63], heart failure [64,65], neuromuscular disease [66,67], spinal cord injury [68], as well as less rigorously designed and executed studies in conditions such as kyphoscoliosis [69] and post-polio [70]. Finally, in a randomised controlled trial, IMT has been shown to offset the myopathic influence of high-dose oral steroids upon inspiratory muscle strength [71].…”